Various studies have suggested the possible cardiovascular (CV) protective effects of the
pneumococcal vaccine (PV). Therefore, we conducted a meta-analysis to assess the …

This systematic review aims to summarize the impact of vaccination against influenza,
shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the …

Coronary artery disease (CAD) covers a wide spectrum from persons who are asymptomatic
to those presenting with acute coronary syndromes (ACS) and sudden cardiac death …

Atherosclerotic cardiovascular diseases (ASCVD) are the major cause of mortality
worldwide. Despite the continuous progress in ASCVD therapy, the residual risk persists …

Background HEARTS in the Americas is the regional adaptation of the WHO Global
HEARTS Initiative. It is implemented in 24 countries and over 2,000 primary healthcare …

Bronchopulmonary infections are a major trigger of cardiac decompensation and are
frequently associated with hospitalizations in patients with heart failure (HF). Adverse …

Influenza, pneumococcal, severe acute respiratory syndrome coronavirus 2, and respiratory
syncytial virus infections are important causes of high morbidity and mortality in the elderly …

The protective effect of the 23-valent pneumococcal polysaccharide vaccine (PPSV23)
against cardiovascular disease has been investigated in the United States and Europe; …

Infections with the pathogen, Streptococcus pneumoniae, are a common cause of morbidity
and mortality worldwide. It particularly affects those at the extremes of age and …

Background: In 2017, the CDC listed heart disease as the leading cause of death, with
pneumonia and influenza being the eighth cause of death. Several studies have suggested …